Alzheimer’s Disease Diagnostics and Therapeutics Market – Global Growth, Trends, COVID-19 Impact, and Forecasts 2021-2026: Focus on Cholinesterase Inhibitors & NMDA Receptor Antagonists – ResearchAndMarkets.com

Alzheimer’s Disease Diagnostics and Therapeutics Market – Global Growth, Trends, COVID-19 Impact, and Forecasts 2021-2026: Focus on Cholinesterase Inhibitors & NMDA Receptor Antagonists – ResearchAndMarkets.com




Alzheimer’s Disease Diagnostics and Therapeutics Market – Global Growth, Trends, COVID-19 Impact, and Forecasts 2021-2026: Focus on Cholinesterase Inhibitors & NMDA Receptor Antagonists – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Alzheimer’s Disease Diagnostics and Therapeutics Market – Growth, Trends, COVID-19 Impact, and Forecasts (2021 – 2026)” report has been added to ResearchAndMarkets.com’s offering.

The Alzheimer’s disease diagnostics and therapeutics market was valued at USD 6,632.82 million in 2020, and it is expected to reach approximately USD 9,073 million in 2026, registering a CAGR of nearly 5.36% during the forecast period, 2021-2026.

The key factors propelling the growth of this market are the increasing prevalence of chronic diseases like dementia, increasing pipeline drug development, investment in biomarkers for drug development, and increasing sophisticated diagnostics for early detection. According to the World Alzheimer Report, in 2019, around 50 million people worldwide were reported to be suffering from Alzheimer’s and related dementia, and this number is further expected to reach 152 million by 2050.

The extensive research studies being conducted related to Alzheimer’s disease are further accelerating the market growth. For instance, in October 2020, ImmunoBrain Checkpoint Inc. was funded USD 1,000,000 by the Alzheimer’s Association to aid the Phase 1 clinical trial for “IBC-Ab002” in the treatment of Alzheimer’s. This is expected to accelerate the market growth.

Also, the National Institute of Health reported that in July 2019, there were 132 agents in clinical trials for AD; 28 agents were in 42 Phase 3 trials, 74 agents were in 83 Phase 2 trials, and 30 agents were in 31 Phase 1 trials. There was an increasing number of agents in each phase compared to the 2018 pipeline. Hence, the increasing number of clinical studies for diagnosis and treatment of Alzheimer’s is expected to drive the market growth.

However, high failure rates of clinical studies related to diagnosis and treatment of Alzheimer’s are expected to hinder the market growth.

Competitive Landscape

The Alzheimer’s disease diagnostics and therapeutics market is moderately competitive and consists of several major players. With technological advancements and product innovation, mid-size to smaller companies are expanding their market presence by introducing new technologies with better results. Companies like F. Hoffmann-La Roche, Novartis AG, Merck & Co., Pfizer Inc., and Eli Lily and Co. hold substantial shares in the market.

Key Topics Covered:

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Use of Biomarkers in Diagnosis and Drug Development

4.2.2 Large Number of Drugs in Pipeline

4.2.3 Emerging Novel Diagnostic Technologies

4.3 Market Restraints

4.3.1 High Failure Rates of Late-stage Drugs

4.3.2 Lack of Surrogate Markers and Challenges in Early Diagnosis

4.4 Porter’s Five Forces Analysis

5 MARKET SEGMENTATION (Market Size by Value)

5.1 By Product

5.1.1 Therapeutics

5.1.1.1 Cholinesterase Inhibitors

5.1.1.2 NMDA Receptor Antagonists

5.1.1.3 Other Therapeutics

5.1.2 Diagnostics

5.1.2.1 Brain Imaging

5.1.2.2 CFS Test for Alzheimer’s Disease

5.2 Geography

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 F. Hoffmann-La Roche

6.1.2 Novartis AG

6.1.3 Merck & Co. Inc.

6.1.4 Pfizer Inc.

6.1.5 Eisai Co. Ltd

6.1.6 Biogen Inc.

6.1.7 Johnson & Johnson

6.1.8 Eli Lilly and Company

6.1.9 Lupin Limited

6.1.10 Abbott Laboratories (Allergna PLC)

6.1.11 Siemens Healthineers

6.1.12 Biogen Inc.

6.1.13 Merz Pharma

6.1.14 Actavis Generics

6.1.15 Adamas Pharmaceuticals Inc.

6.1.16 Sun Pharmaceuticals

6.1.17 Corium International Inc.

6.1.18 Grifols SA

6.1.19 Amgen Inc. (Vigil Neuroscience)

6.1.20 Luye Pharma

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/8f86mm

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900